Bosoga v Sambo (CT02750ADJ2026) [2026] COMPTRI 79 (1 August 2026)

60 Reportability

Brief Summary

Companies — Removal of director — Application for removal of director under section 71(8)(b) of the Companies Act — Applicant alleging negligence and dereliction of duties by Respondent — Respondent failing to respond to application and engaging in actions detrimental to the company — Tribunal finding sufficient grounds for removal — Respondent removed as director of BOSAPHARMACY AND CLINIC (PTY) LTD.

1
SAFLII Note: Certain personal/private details of parties or witnesses have been redacted from this
document in compliance with the law and SAFLII Policy

IN THE COMPANIES TRIBUNAL OF SOUTH AFRICA



CASE NO: CT02750ADJ2026

In the matter between:

HEROLD PITSO BOSOGA Applicant

and

TUMELO SAMBO Respondent

Date of Decision: 1
st August 2026


DECISION


INTRODUCTION
1. The Applicant is HEROLD PITSO BOSOGA (ID Number 8[…] ) a
director of BOSAPHARMACY AND CLINIC (PTY) LTD (Registration
2025/546239/07).

2. The Respondent is TUMELO SAMBO (ID Number 9[…] ) a director of
BOSAPHARMACY AND CLINIC (PTY) LTD (Registration2025/546239/07).

3. This is an application in terms of sections 71(8)(b) of the Companies
Act No. 71 of 2008 (‘’the Act’’) for an Administrative Order determining the
removal of the Third Respondent as a director.

2

APPLICANT’S SUBMISSIONS

4. This is an application wherein The Applicant is requesting the Tribunal
to make an order for the Respondent to be removed as director.

5. The Applicant served all documents to Mr. Sambo on 20 May 2026 via
registered mail to his email address: (which he uses for all company
communications).. Mr. Sambo chose not to respond to the case. He has not
communicated with the Applicant since 20 May 2026, except on 24 June
2026, when he unilaterally added another director. Mr. Sambo had 20
working days to respond, which ended on 18 June 2026.

6. Due to his disregard for the law and procedure, The Applicant
requested a default judgment removing him as a director with effect from 19
June 2026, for the following reasons:

7. Conflict of Interest Mr. Sambo is an employee of SANULAC and works
Monday to Friday. He is also a dedicated church member who never misses
a Sunday service, making him available only on some Saturdays. He rarely
assists at the pharmacy and always has an excuse. The pharmacy opened
on 1 February 2026 and is operating at a loss, requiring full support. The
Applicant offered to buy him out, but he refused. The company’s MO I
(Clause 3) states that shareholders have pre- emptive rights to be offered
additional shares. Mr. Sambo claims he is selling his shares to his uncle,

3
which breaches the MOI. The Applicant advised him to follow proper
procedure (business evaluation, share valuation, and sale agreement), but
he refused, stating his uncle will buy regardless of value. His uncle is
opening a medical center and pharmacy nearby and already has a
pharmacist ready. The uncle has already received confidential business
information (Annexure A). In terms of GRN 553 of April 2003 (Regulations
relating to the ownership and licensing of Pharmacies), Chapter 1,
Regulation 4, an authorized prescriber cannot own a pharmacy. Mr. Sambo’s
uncle, Dr. Manganyi, is an authorized prescriber. Mr. Sambo’s close
relationship with his uncle (who paid his final year fees, Annexure I) further
indicates he prioritizes his uncle’s interests over the business.

8. Sabotage of the Business · Responsible Pharmacist (RP): Our RP,
Mr. Khotle, resigned on 21 February 2026. We operated with a locum. Mr.
Sambo promised to find a new RP (Mr. Keke) but withdrew the offer just
before a scheduled inspection on 30 March 2026. This put the pharmacy at
risk of fines or license revocation. F ortunately the inspection did not occur,
and The Applicant later found an RP. (Annexure C).

9. Unauthorized Access to Suppliers: On 19 February 2026, The
Applicant gave Mr. Sambo login credentials to audit accounts, with the verbal
agreement that he would not place personal orders. On 20 February 2026,
he placed a personal order from his laptop. The Applicant cancelled it and he
claimed it was a test. He later requested the same items be ordered for him
from the pharmacy.

4

10. Illegal Medication Order: On 13 March 2026, tThe Applicant notified
Mr. Sambo the pharmacy would be closed on 14 March 2026. On Sunday,
15 March, he placed an order for Microcidal 500MG (a scheduled medication
requiring a prescription), which is illegal under the Medicines and Related
Substances Act (Act 101 of 1965), Section 22A.

11. Disruption of Supply: Because he placed an unpaid order on Sunday,
the supplier prioritized his order, delaying our pharmacy’s urgent client
orders. The Applicant cancelled his order to prioritize pharmacy clients The
Applicant then deactivated his remote access to protect the business. The
Applicant have consistently advised him to use the systems at the pharmacy
during working hours.

12. Disruption of Utility Infrastructure The pharmacy relies on Wi-FI for its
operating system (Allegra), medical aid claims, and pricing. On the week of
19 February, The Applicant asked Mr. Sambo to buy a Wi -FI router on a
month-to-month contract, billing the pharmacy. Instead, he took a 24- month
contract under his name and personal bank account and requested monthly
reimbursements. On 20 April 2026, after a dispute with staff over free
hypertension medication, he threatened to take the router away, saying we
must "make a plan." The Applicant subsequently purchased a router from
MTN on a month- to-month contract using the company's registration letter,
ID, and proof of residence—documents Mr. Sambo had on hand in February
but chose not to use

5

13. Sharing Information with the Competition. Since his remote access
was disabled, Mr. Sambo has repeatedly shared the pharmacy's financials,
partnership agreements, and operational matters with his uncle, who is
opening a competing medical centre nearby . Under pharmacy regulations, a
new pharmacy cannot be located within 500 meters of an existing community
pharmacy. His uncle’s property is within this radius. The Applicant believe
Mr. Sambo is colluding to sabotage our pharmacy to allow his uncle’s
business to succeed.

14. Breach of Director Duties and Unilateral Actions · Staff Issues: Mr.
Sambo disputes existing agreements with staff (Zanele Nkos i and the
Applicants wife, Abigail Bosoga) despite their involvement preceding the
pharmacy’s opening. He refused to draft employment contracts but later
demanded they be done. He told staff they were fired and had to vacate.

15. Financial Burden: Mr. Sambo refuses to contribute financially, while
The Applicant funds all salaries, rent, stock, and maintenance.

16. Clinic Non -Operation: He refuses to draft a lease contract for the
clinic, leaving it non- operational despite daily client demand. This denies the
pharmacy additional revenue.

17. Computer Equipment: He bought three used computers; one for the
clinic was faulty and remains unrepaired despite my reminders.

6

18. Default and Unilateral Director Appointment The Applicant has
continuously explained that he has access to suppliers only at the pharmacy,
which he refuses to accept. Since 20 May 2026, he has been unresponsive.
On 24 June 2026 (three days after his response deadline), Mr. Sambo
informed the Applicant via WhatsApp that he had appointed a new director
and sold his shares. A few minutes later, The Applicant received a CIPC
email confirming the appointment of Mr. Mmatlala Phyllix Sekalo as a new
director.

19. The Applicant did not consent to this. No meeting was held, no
agreement made, and the Applicant has never met this new director. The
Applicant received no SMS or email OTP for this change, which suggests Mr.
Sambo fraudulently altered the details with CIPC.

20. As of this date, no records of the share sales, financial settlement, or
SARS declarations exist. This exposes the company to lawsuits, potential
money laundering investigations, and tax evasion claims.

21. Prayer for Relief The Applicant request that if a default judgment is
granted in his favor: All actions by Mr. Sambo after 18 June 2026 be
declared unlawful. Both Mr. Tumelo Sambo and the newly appointed director,
Mr. Sekalo Mmatlala Phyllix, be removed as directors of BOSAPHARMACY
AND CLINIC (PTY) LTD.

APPLICABLE LAW

7
22. Section 71 (removal of directors) is the applicable section of the Act.
71 of the Act provides as follows:Removal of directors

71. (1) Despite anything to the contrary in a company’s Memorandum
of Incorporation or rules, or any agreement between a company and a
director, or between any shareholders and a director, a director may
be removed by an ordinary resolution adopted at a shareholders
meeting by the persons entitled to exercise voting rights in an election
of that director, subject to subsection (2). (2) Before the shareholders
of a company may consider a resolution contemplated in subsection
(1)— (a) the director concerned must be given notice of the meeting
and the resolution, at least equivalent to that which a shareholder is
entitled to receive, irrespective of whether or not the director is a
shareholder of the company; and (b) thedirector must be afforded a
reasonable opportunity to make a presentation, in person or through a
representative, to the meeting, before the resolution is put to a vote.
(3) If a company has more than two directors, and a shareholder or
director has alleged that a director of the company — (a) has
become— (i) ineligible or disqualified in terms of section 69, other than
on the grounds contemplated in section 69(8)(a);or (ii) incapacitated to
the extent that the director is unable to perform the functions of a
director, and is unlikely to regain that capacity within a reasonable
time; or (b) hasneglected, or been derelict in the performance of, the
functions of director, the board, other than the director concerned,
must determine the matter by resolution, and may remove a director

8
whom it has determined to be ineligible or disqualified, incapacitated,
or negligent or derelict, as the case may be. (4) Before the board of a
company may consider a resolution contemplated in subsection (3),
the director concerned must be given— (a) notice of the meeting,
including a copy of the proposed resolution and a statement setting
out reasons for the resolution, with sufficient specificity to reasonably
permit the director to prepare and present a response; and (b) a
reasonable opportunity to make a presentation, in person or through a
representative, to the meeting before the resolution is put to a vote. (5)
If, in terms of subsection (3), the board of a company has determined
that a director is ineligible or disqualified, incapacitated, or has been
negligent or derelict, as the case may be, the director concerned, or a
person who appointed that director as contemplated in section
66(4)(a)(i), if applicable, may apply within 20 business days to a court
to review the determination of the board. (6) If, in terms of subsection
(3), the board of a company has determined that a director is not
ineligible or disqualified, incapacitated, or has not been negligent or
derelict, as the case may be— (a) any director who voted otherwise on
the resolution, or any holder of voting rights entitled to be exercised in
the election of that director, may apply to a court to review the
determination of the board; and (b) the court, on application in terms of
paragraph (a), may— (i) confirm the determination of the board; or (ii)
remove the director from office, if the court is satisfied that the director
is ineligible or disqualified, incapacitated, or has been negligent or
derelict. (7) An applicant in terms of subsection (6) must compensate

9
the company, and any other party, for costs incurred in relation to the
application, unless the court reverses the decision of the board. (8) If a
company has fewer than three directors — (a) subsection (3) does not
apply to the company; (b) in any circumstances contemplated in
subsection (3), any director or shareholder of the company may apply
to the Companies Tribunal, to make a determination contemplated in
that subsection; and 5 10 15 20 25 30 35 40 45 50 55142 (c)
subsections (4), (5) and (6), each read with the changes required by
the context, apply to the determination of the matter by the Companies
Tribunal. (9) Nothing in this section deprives a person removed from
office as a director in terms of this section of any right that person may
have at common law or otherwise to apply to a court for damages or
other compensation for— (a) loss of office as a director; or (b) loss of
any other office as a consequence of being removed as a director.
(10) This section is in addition to the right of a person, in terms of
section 162, to apply to a court for an order declaring a director
delinquent, or placing a director on probation
EVALUATION AND FINDINGS

23. The main issue is whether the Respondent has been negligent or
derelict in her duties as director.

24. Having considered the provisions of section 71 I am convinced that the
Respondent has acted negligently . The Respondent has acted in his
personal interest at the expense of the company. The Respondent had made

10
personal medication orders using the companies account. This put the
company at risk as some of the medication needed a prescription. He put
customers orders at risk The Respondent took away a router that was
needed by the company . The Respondent appointed a director without
consultation with the Applicant.

25. The Tribunal finds that it is thus in the best interest of the company for
the Respondent to be removed as director.

26. I however cannot make an order for the removal of Mr. Sekalo
Mmatlala Phyllix as director as he is not a party to this dispute. Neither can I
make an order declaring all the Respondents actions as invalid as my
jurisdiction is limiting to removing the Respondent as a director.

ORDER

27. The relief sought by The Applicant is granted.

a. The Respondent is removed as a director of
BOSAPHARMACY AND CLINIC (PTY) LTD (Registration
2025/546239/07) in terms of Section 71(8) of the Act.
b. The Companies and Intellectual Property Commission is
hereby ordered
to deregister TUMELO SAMBO (ID Number
9[…] ) as a director of BOSAPHARMACY AND CLINIC (PTY)
LTD (Registration 2025/546239/07) within a period of 10
(ten) days from receipt of this order.

11
c. The Registrar of the Tribunal is hereby directed to deliver a
copy of this order to the Commissioner of Companies
and Intellectual Property Commission within 5 (five) days
from date of this order.

MOHAMED ALLTHE APPLICANTCHICKTAY
MEMBER OF THE COMPANIES TRIBUNAL